GT Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 14, 2024 16:05 ET
|
GT Biopharma, Inc.
GTB-3650 TriKE® Phase 1 trial initiation expected in 2H 2024; initial clinical data expected in 1H 2025GTB-5550 TriKE® IND submission for treatment of B7H3 positive solid tumors expected in 1H...
GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 14, 2024 08:05 ET
|
GRI Bio, Inc.
Company focused on execution of lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) GRI-0621 interim data readout of Phase 2a biomarker study on track for Q4 2024 and...
Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 01, 2024 07:30 ET
|
Arbutus Biopharma Corporation
End-of-treatment data presented at the EASL Congress from two Phase 2a clinical trials supports advancing imdusiran as a potential cornerstone in a HBV functional cure treatment regimen IM-PROVE I...
Aridis Provides Corporate Update
June 24, 2024 17:58 ET
|
Aridis Pharmaceuticals, Inc.
LOS GATOS, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, today announced a corporate update on recent...
Mise à jour corporative de Kintavar
May 29, 2024 07:43 ET
|
Kintavar Exploration inc.
MONTRÉAL, 29 mai 2024 (GLOBE NEWSWIRE) -- Kintavar Exploration Inc. (la « Société » ou « Kintavar ») (TSX-V : KTR), est heureuse de fournir une mise à jour corporative détaillant les objectifs...
Kintavar Corporate Update
May 29, 2024 07:43 ET
|
Kintavar Explorations Inc.
MONTREAL, May 29, 2024 (GLOBE NEWSWIRE) -- Kintavar Exploration Inc. (the “Corporation” or “Kintavar”) (TSX-V: KTR), is pleased to provide a corporate update detailing the Corporations objectives...
Odysight.ai Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 16, 2024 08:30 ET
|
Odysight.ai Inc.
OMER, Israel, May 16, 2024 (GLOBE NEWSWIRE) -- Odysight.ai Inc. (OTCQB: ODYS), a leading provider of visual based predictive maintenance (PdM) and condition-based monitoring (CBM) solutions,...
Optimi Health Provides Corporate Update
May 10, 2024 08:50 ET
|
Optimi Health Corp.
Optimi Health provides corporate update.
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 02, 2024 07:30 ET
|
Arbutus Biopharma Corporation
End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024 Preliminary data from the single-dose portion of the AB-101-001...
NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility
April 25, 2024 08:35 ET
|
NurExone Biologic Inc
NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility